300026SZSE

Legal Opinion for the 2025 Annual Shareholders' Meeting

Tianjin Chasesun Pharmaceutical Co., Ltd.·May 20, 2026·7 pages

✨ AI Summary

This legal opinion confirms that the 2025 Annual Shareholders' Meeting of Tianjin Hongri Pharmaceutical Co., Ltd. was convened and conducted in compliance with relevant laws and regulations. Key figures include 996,068,708 shares represented (33.1564% of total shares). Material outcomes include the approval of the 2025 Annual Work Report (99.2705%), 2025 Annual Financial Allocation (97.6582%), 2026 Annual Related Transactions (99.1816%), and the appointment of directors (99.2595%). The meeting's procedures and results are deemed legal and effective.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Beijing Jincheng Tongda & Neal Law Firm

Regarding Tianjin Hongri Pharmaceutical Co., Ltd.

Legal Opinion for the 2025 Annual Shareholders' Meeting

To: Tianjin Hongri Pharmaceutical Co., Ltd.

Beijing Jincheng Tongda & Neal Law Firm (hereinafter referred to as "this Firm") accepts the appointment by Tianjin Hongri Pharmaceutical Co., Ltd. (hereinafter referred to as "Hongri Pharmaceutical" or "the Company") to provide legal opinions regarding the 2025 Annual Shareholders' Meeting (hereinafter referred to as "this Meeting") and related matters.

This Firm is based on the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Articles of Association of the Company, and other relevant laws and regulations, and has conducted a legal review of the convening of this Meeting.

This Firm hereby states:

This legal opinion is solely for the purpose of this Meeting and may not be used for any other purpose.
This Firm has already been informed of the relevant matters regarding this Meeting and has verified the legality and compliance of the documents provided by the Company.

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.